Literature DB >> 22943170

Long-term stability of quercetin nanocrystals prepared by different methods.

Mitali Kakran1, Ranjita Shegokar, Nanda Gopal Sahoo, Sven Gohla, Lin Li, Rainer H Müller.   

Abstract

OBJECTIVES: This study aimed to examine the long-term physical stability of quercetin nanocrystals produced by three methods.
METHODS: Quercetin nanocrystals were prepared by high pressure homogenization, bead milling and cavi-precipitation. The nanocrystals produced by these methods were compared for particle size, saturation solubility and dissolution of the drug particles, and were subjected to stability testing. KEY
FINDINGS: The X-ray diffraction study and microscopic pictures taken under polarized light indicated the crystalline nature of the nanocrystals produced by the three methods. As the crystalline state is relatively more stable than the amorphous state, a good physical stability was expected from the quercetin nanocrystals prepared. The high-pressure homogenized and bead-milled quercetin nanocrystals showed excellent physical stability when stored under refrigeration (4±2°C) and at room temperature (25±2°C) for 180 days. The dissolution properties were not significantly affected on storage at room temperature. However, increase in the storage temperature to 40±2°C led to physical instability. On the other hand, the cavi-precipitated quercetin nanocrystals exhibited a lower stability than the bead-milled and homogenized formulations and did not show the optimum zeta potential values as well. In the case of cavi-precipitated nanocrystals, recrystallization and agglomeration were responsible for the increasing particle size besides the Ostwald ripening phenomenon. The solvents used during cavi-precipitation might have competed with the surfactant for hydration leading to a partial dehydration of the surfactant, which subsequently affected the stability of the quercetin nanocrystals.
CONCLUSIONS: High-pressure homogenized and bead-milled quercetin nanocrystals showed better physical stability than the cavi-precipitated ones. Freeze drying immediately after nanocrystal production can help to prevent their agglomeration and thus improve physical stability.
© 2012 The Authors. JPP © 2012 Royal Pharmaceutical Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22943170     DOI: 10.1111/j.2042-7158.2012.01515.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  6 in total

1.  Improved Antioxidant Capacity of Black Tea Waste Utilizing PlantCrystals.

Authors:  Abraham M Abraham; Reem M Alnemari; Jana Brüßler; Cornelia M Keck
Journal:  Molecules       Date:  2021-01-23       Impact factor: 4.411

2.  Facile production of quercetin nanoparticles using 3D printed centrifugal flow reactors.

Authors:  Davide De Grandi; Alireza Meghdadi; Gareth LuTheryn; Dario Carugo
Journal:  RSC Adv       Date:  2022-07-19       Impact factor: 4.036

3.  Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.

Authors:  Sanyog Jain; Venkata Appa Reddy; Sumit Arora; Kamlesh Patel
Journal:  Drug Deliv Transl Res       Date:  2016-10       Impact factor: 4.617

Review 4.  Nanocrystals of Poorly Soluble Drugs: Drug Bioavailability and Physicochemical Stability.

Authors:  Maria Rosa Gigliobianco; Cristina Casadidio; Roberta Censi; Piera Di Martino
Journal:  Pharmaceutics       Date:  2018-08-21       Impact factor: 6.321

5.  Gallic Acid and Quercetin as Intelligent and Active Ingredients in Poly(vinyl alcohol) Films for Food Packaging.

Authors:  Francesca Luzi; Elisa Pannucci; Luca Santi; José Maria Kenny; Luigi Torre; Roberta Bernini; Debora Puglia
Journal:  Polymers (Basel)       Date:  2019-12-03       Impact factor: 4.329

Review 6.  Progress in the development of stabilization strategies for nanocrystal preparations.

Authors:  Jingru Li; Zengming Wang; Hui Zhang; Jing Gao; Aiping Zheng
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.